Neurogene logo
Neurogene
NGNE | NASDAQ
Chart Builder DCF Calculator
$23.30
-$0.63 (-2.63%)
At close: Nov 16, 2026, 4:00 PM ET
$23.30
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Neurogene Company Profile

Company profile explained

Company Profile

Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.

Key Executives

Name Position
Rachel L. McMinn Founder, Executive Chair & Chief Executive Officer
Andrew E. Mulberg FAAP Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control
Arvind Sreedharan Senior Vice President of Business Operations
Christina Shafer Chief Commercial Officer
Christine Mikail Cvijic President, CFO & Director
Donna Cochener-Metcalfe Senior Vice President, General Counsel & Corporate Secretary
Julie Jordan Chief Medical Officer
Lina Li Executive Director of Investor Relations
Ricardo Jimenez Senior Vice President of Technical Operations
Stuart Cobb Chief Scientific Officer
Neurogene
Neurogene logo
Country United States
IPO Date Mar 7, 2014
Industry Biotechnology
Sector Healthcare
Employees 131
CEO Rachel L. McMinn

Contact Details

535 W 24th Street New York City, New York 10011 United States

Stock Details

Ticker Symbol NGNE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001404644
CUSIP Number 64135M105
ISIN Number US64135M1053
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.